Abstract:Introduction Diffuse large B-cell lymphoma (DLBCL) is a disease with high molecular and genetic heterogeneity, giving challenges to research and therapy in relation to prognosis. Ferroptosis, a form of regulated cell death, is produced by excessive lipid peroxidation. Induction of ferroptosis may be a promising therapeutic strategy contributed to triggering cancer cell death. However, the function of ferroptosis in DLBCL and its under mechanism are still undefined, especially the interaction with the tumor immune microenvironment (TIME). Here, we aimed to systematically investigate novel prognostic biomarkers by ferroptosis-related genes (FRGs) and explore their connection with TIME in DLBCL. Methods RNA sequencing (RNA-seq) data and corresponding clinical information of DLBCL patients (n=928) were analyzed. The differential expression of FRGs was determined and the prognostic risk signatures were analyzed. Kaplan-Meier survival analysis, univariate and multivariate Cox regression analyses and receiver operating characteristic (ROC) curve analysis were performed. The potential functions of FRGs in DLBCL were explored using GO, KEGG enrichment and single-sample gene set enrichment analysis (ssGSEA). The immunoscore was calculated utilizing the ESTIMATE algorithm. Results To evaluate the effect of ferroptosis genes in DLBCL progression, we systematically explored the expression patterns of 60 FRGs and found that most of them were dysregulated. Subsequently, the effect of ferroptosis genes in the clinical prognosis of DLBCL patients was probed. 10 genes were identified based on the LASSO algorithm to calculate the risk score. The low-risk group showed significantly prolonged OS in DLBCL patients. Furthermore, to evaluate the prognostic accuracy of the risk signatures, we performed 1-, 2-, and 3-year ROC curve analyses and the respective AUC values displayed the reliability of the prediction. The clinicopathological features between high-risk group and low-risk group were next evaluated, risk score was shown a significant relevance to IPI and ECOG (p<0.05; Figure 1). Univariate and multivariate Cox regression analyses indicated that risk signature was implicated in OS and can be identified as an independent indicator in DLBCL patients. GO and KEGG enrichment analysis were used to probe the biological function of ferroptosis genes and the results revealed the remarkably enriched in inflammatory cell activation, immune response, and PD-L1 checkpoint pathway. Therefore, we speculated that ferroptosis can modulate the composition of the TIME, and then assessed the enrichment degrees of immune cells and the activity of immune-related pathways between high- and low-risk groups through the ssGSEA. Subsequently, CIBERSORTx was utilized to calculate the abundance ratios of 22 types of immune cells for exploring the microenvironment components of DLBCL patients (Figure 2). The immune cell interaction in TIME was observed by the correlation coefficient heatmap. We finally found that the immunoscore of the low-risk group and the expression levels of PD-L1, a vital immune checkpoint, were higher than those of the high-risk group. Conclusions We identified that ferroptosis genes were dysregulated and ferroptosis genes-based risk score was an independent prognostic indicator of DLBCL patients. More importantly, our study indicated that ferroptosis genes-based risk signatures were remarkably related to the immune cell infiltration levels, and ferroptosis might participate in the regulation of DLBCL immune microenvironment. Further assessment of the ferroptosis patterns in DLBCL may improve the comprehension of immune infiltrations, contributing to achieving individualized immunotherapeutic strategies for this patient population. Keywords: ferroptosis, prognosis, tumor immune microenvironment, immunotherapy, DLBCL Disclosure No conflicts of interest to declare. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

FDX1 promotes elesclomol-induced PANoptosis in diffuse large B-cell lymphoma by activating IRF3/IFN-β signaling

AB017. NFκB1 Regulates FDX1 to Facilitate Elesclomol-Induced Cuproptosis Against Glioblastoma

FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis

Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration

Activated Interferon-Γ (Ifn-Γ) Pathway Associated with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1)/PD Ligand 1 (Pd-L1)-based Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker

Pan-cancer Integrated Bioinformatics Analysis Reveals Cuproptosis Related Gene FDX1 is a Potential Prognostic and Immunotherapeutic Biomarker for Lower-Grade Gliomas

Prognostic and Immunological Role of Cuproptosis-Related Protein FDX1 in Pan-Cancer

Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma

Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma

Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis

Multi-omics pan-cancer study of cuproptosis core gene <i>FDX1</i> and its role in kidney renal clear cell carcinoma

Integrated Analyses Reveal the Prognostic, Immunological Features and Mechanisms of Cuproptosis Critical Mediator Gene FDX1 in KIRC.

Multiple Omics Analysis Reveals E2F5 Predict Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma

Prognostic and Immunological Role of FDX1 in Pan-Cancer: an In-Silico Analysis

Comprehensive Analysis of the Prognosis and Immune Infiltrates of Ferroptosis-Related Genes in Diffuse Large B-Cell Lymphoma

LINC02362/hsa-miR-18a-5p/FDX1 Axis Suppresses Proliferation and Drives Cuproptosis and Oxaliplatin Sensitivity of Hepatocellular Carcinoma.

FBXL10 Contributes to the Development of Diffuse Large B-cell Lymphoma by Epigenetically Enhancing ERK1/2 Signaling Pathway

FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production